Premium
Timolol Maleate, A Beta Blocker, In the Treatment of Common Migraine Headache
Author(s) -
Gallagher R. Michael,
Stagliano Robert A.,
Sporazza Carl
Publication year - 1987
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1987.hed2702084.x
Subject(s) - migraine , timolol , headaches , medicine , anesthesia , beta blocker , surgery , ophthalmology , glaucoma , heart failure
SYNOPSIS Timolol maleate, a beta blocker, has been shown to reduce the frequency of common migraine headache in clinical trials. An analysis of 116 patients treated prophylactically for common migraine with timolol maleate 10–30 mg. per day was conducted. There were 35 males and 81 females ranging in age from 19 to 61 years; they experienced 3 to 8 headaches per month. After 6 months 11 patients (9%) showed > 75% improvement, 47 patients (41%) showed 50–74% improvement, 31 patients (27%) showed 25–49% improvement, 23 patients (20%) showed <25% improvement, and 4 patients (3%) discontinued because of side effects. This limited study suggests that timolol maleate may be of benefit in the treatment of some migraine patients.